Bone marrow mononuclear cell therapy in experimental allergic asthma: Intratracheal versus intravenous administration
Bone marrow mononuclear cell therapy in experimental allergic asthma: Intratracheal versus intravenous administration
复制标题
DOI：
10.1016/j.resp.2012.11.005
复制
发表时间：
2013-02-01
影响因子：
2.3
通讯作者：
Rocco, Patricia R. M.
中科院分区：
文献类型：
--
作者：
Abreu, Soraia C.;Antunes, Mariana A.;Rocco, Patricia R. M.
我们假设政府将的途径影响骨髓源性单核细胞（bmmdmc）治疗对哮喘重塑过程的有益作用。C57BL/6小鼠随机分为两组。在OVA组中，小鼠被致敏并被卵清蛋白激发，而对照组则使用相同的方案接受生理盐水。在第一次给药前24小时，对照组和OVA动物进一步随机分为三个亚组，分别接受生理盐水（SAL）、BMDMCs静脉注射（2 × 10(6)）或BMDMCs气管注射（2 × 10(6)）。无论给药途径如何，BMDMC治疗均可引起OVA小鼠的以下变化：气道和肺实质中阻力和粘弹性压力、静弹性、嗜酸性粒细胞浸润、胶原纤维含量降低；降低白细胞介素(IL)-4、IL-13、转化生长因子- β和血管内皮生长因子的水平。总之，无论给药途径如何，BMDMC都能调节过敏性哮喘实验模型的炎症和重塑过程。(C) 2012 Elsevier B.V.版权所有
We hypothesized that the route of administration would impact the beneficial effects of bone marrow-derived mononuclear cell (BMDMC) therapy on the remodelling process of asthma. C57BL/6 mice were randomly assigned to two main groups. In the OVA group, mice were sensitized and challenged with ovalbumin, while the control group received saline using the same protocol. Twenty-four hours before the first challenge, control and OVA animals were further randomized into three subgroups to receive saline (SAL), BMDMCs intravenously (2 x 10(6)), or BMDMCs intratracheally (2 x 10(6)). The following changes were induced by BMDMC therapy in OVA mice regardless of administration route: reduction in resistive and viscoelastic pressures, static elastance, eosinophil infiltration, collagen fibre content in airways and lung parenchyma; and reduction in the levels of interleukin (IL)-4, IL-13, transforming growth factor-beta and vascular endothelial growth factor. In conclusion, BMDMC modulated inflammatory and remodelling processes regardless of administration route in this experimental model of allergic asthma. (C) 2012 Elsevier B.V. All rights reserved.